NASDAQ: AKBAAkebia Therapeutics Inc Stock
$0.67-0.03 (-4.29%)
Updated Mar 22, 2023
AKBA Price
$0.67
Fair Value Price
$1.19
Market Cap
$122.89M
52 Week Low
$0.24
52 Week High
$2.60
P/E
-1.31x
P/B
13.15x
P/S
0.36x
PEG
N/A
Dividend Yield
N/A
Revenue
$292.60M
Earnings
-$92.56M
Gross Margin
71%
Operating Margin
-26.27%
Profit Margin
-31.6%
Debt to Equity
36.66
Operating Cash Flow
-$73M
Beta
1.51
Next Earnings
May 8, 2023
Ex-Dividend
N/A
Next Dividend
N/A
AKBA Overview
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AKBA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AKBA ($0.67) is undervalued by 44.03% relative to our estimate of its Fair Value price of $1.19 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AKBA ($0.67) is significantly undervalued by 44.03% relative to our estimate of its Fair Value price of $1.19 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
AKBA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AKBA due diligence checks available for Premium users.
Be the first to know about important AKBA news, forecast changes, insider trades & much more!
AKBA News
Valuation
AKBA fair value
Fair Value of AKBA stock based on Discounted Cash Flow (DCF)
Price
$0.67
Fair Value
$1.19
Undervalued by
43.78%
AKBA ($0.67) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AKBA ($0.67) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AKBA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AKBA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.31x
Industry
16.9x
Market
22.44x
AKBA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
13.15x
Industry
4.76x
AKBA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AKBA's financial health
Profit margin
Revenue
$55.2M
Net Income
-$7.6M
Profit Margin
-13.7%
AKBA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AKBA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$351.8M
Liabilities
$342.5M
Debt to equity
36.66
AKBA's short-term assets ($184.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKBA's long-term liabilities ($217.73M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKBA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AKBA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$54.7M
Investing
$0.0
Financing
-$1.0k
AKBA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AKBA vs Biotech Stocks
Akebia Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.